

PHARMACOEPIDEMOLOGY

EUROmediCAT signal detection: an evaluation of selected congenital anomaly-medication associations

Correspondence Professor Helen Dolk, Room 12L14, School of Nursing, University of Ulster, Jordanstown Campus, Shore Road, Newtownabbey, Co. Antrim BT37 0QB, UK. Tel.: +44 28 9036 8540; Fax: +44 28 9036 8341; E-mail: h.dolk@ulster.ac.uk

Received 17 November 2015; **revised** 21 March 2016; **accepted** 23 March 2016

Joanne E. Given¹, Maria Loane¹, Johannes M. Luteijn², Joan K. Morris², Lolkje T.W. de Jong van den Berg³, Ester Garne⁴, Marie-Claude Addor⁵, Ingeborg Barisic⁶, Hermien de Walle⁷, Miriam Gatt⁸, Kari Klungsoyr⁹, Babak Khoshnood¹⁰, Anna Latos-Bielenska¹¹, Vera Nelen¹², Amanda J. Neville¹³, Mary O'Mahony¹⁴, Anna Pierini¹⁵, David Tucker¹⁶, Awi Wiesel¹⁷ and Helen Dolk¹⁸

¹Centre for Maternal, Fetal and Infant Research, Institute of Nursing and Health Research, Ulster University, United Kingdom, ²Wolfson Institute of Preventive Medicine, Queen Mary University of London, United Kingdom, ³Department of Pharmacy, University of Groningen, the Netherlands, ⁴Paediatric Department, Hospital Lillebaelt, Kolding, Denmark, ⁵Division of Medical Genetics, CHUV, Lausanne, Switzerland, ⁶Department of Medical Genetics and Reproductive Health, Children's University Hospital Zagreb, Croatia, ⁷Eurocat Northern Netherlands, University of Groningen, University Medical Center Groningen, Department of Genetics, Groningen, the Netherlands, ⁸Department of Health Information and Research, Guardamangia, Malta, ⁹Medical Birth Registry of Norway, the Norwegian Institute of Public Health and Department of Global Public Health and Primary Care, University of Bergen, Norway, ¹⁰Paris Registry of Congenital Anomalies, Obstetrical, Perinatal and Pediatric Epidemiology Research Team, Center for Biostatistics and Epidemiology, INSERM U1153, Maternité de Port-Royal, PARIS, France, ¹¹Polish Registry of Congenital Malformations, Department of Medical Genetics, Poznan, Poland, ¹²Provinciaal Instituut voor Hygiene (PIH), Antwerp, Belgium, ¹³IMER Registry (Emilia Romagna Registry of Birth Defects), Centre for Clinical and Epidemiological Research, University of Ferrara and Azienda Ospedaliero Univerisitarion di Ferrara, Italy, ¹⁴Health Service Executive, Cork, Ireland, ¹⁵Epidemiology and Health Promotion Macro-Area Working Group, Unit of Environmental Epidemiology and Disease Registries, CNR Institute of Clinical Physiology, Pisa, Italy, ¹⁶CARIS – Congenital Anomaly Register and Information Service for Wales, Public Health Wales, Swansea, United Kingdom, ¹⁷Mainz Model Birth Registry, University Children's Hospital Mainz, Germany and ¹⁸Centre for Maternal, Fetal and Infant Research, Institute of Nursing and Health Research, Ulster University, United Kingdom

Keywords congenital anomalies, drug-induced anomalies, pharmacoepidemiology, pharmacovigilance, pregnancy, signal evaluation

AIMS

To evaluate congenital anomaly (CA)-medication exposure associations produced by the new EUROmediCAT signal detection system and determine which require further investigation.

METHODS

Data from 15 EUROCAT registries (1995–2011) with medication exposures at the chemical substance (5th level of Anatomic Therapeutic Chemical classification) and chemical subgroup (4th level) were analysed using a 50% false detection rate. After excluding antiepileptics, antidiabetics, antiasthmatics and SSRIs/psycholeptics already under investigation, 27 associations were evaluated. If evidence for a signal persisted after data validation, a literature review was conducted for prior evidence of human teratogenicity.

RESULTS

Thirteen out of 27 CA-medication exposure signals, based on 389 exposed cases, passed data validation. There was some prior evidence in the literature to support six signals (gastroschisis and levonorgestrel/ethinylestradiol (OR 4.10, 95% CI 1.70–8.53; congenital heart disease/pulmonary valve stenosis and nucleoside/tide reverse transcriptase inhibitors (OR 5.01, 95% CI 1.99–14.20/OR 28.20, 95% CI 4.63–122.24); complete absence of a limb and pregnen (4) derivatives (OR 6.60, 95% CI 1.70–22.93); hypospadias and pregnadien derivatives (OR 1.40, 95% CI 1.10–1.76); hypospadias and synthetic ovulation stimulants (OR 1.89, 95% CI 1.28–2.70). Antipropulsives produced a signal for syndactyly while the literature revealed a signal for hypospadias. There was no prior evidence to support the remaining six signals involving the ordinary salt combinations, propulsives, bulk-forming laxatives, hydrazinophthalazine derivatives, gonadotropin releasing hormone analogues and selective serotonin agonists.

CONCLUSION

Signals which strengthened prior evidence should be prioritized for further investigation, and independent evidence sought to confirm the remaining signals. Some chance associations are expected and confounding by indication is possible.

WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT

- There is insufficient information on the safety of the vast majority of medications when taken during pregnancy and more post-marketing surveillance of medication safety in pregnancy is needed.
- Signal detection based on spontaneous adverse effect reporting is biased and incomplete.

WHAT THIS STUDY ADDS

- The EUROmediCAT database, comprising data from population-based EUROCAT congenital anomaly registries, can be used for systematic signal detection and signal strengthening.
- Our results strengthen six congenital anomaly-medication exposure signals in the literature.
- We generated seven new signals which require independent confirmation as some may be chance findings.

Introduction

Congenital anomalies (CAs), structural or functional abnormalities that are present from birth [1], are a major cause of infant mortality, childhood morbidity and long-term disability [2]. They are a diverse group of disorders of prenatal origin and can be caused by a wide range of factors such as genetics, environmental agents, medications and physical conditions [3–5]. While a number of antenatal medication exposures are known to cause CAs [6], there is insufficient information on the risks and safety for the vast majority of medications [7]. The critical period for most major CAs is during organogenesis, in the first trimester of pregnancy [8]. It has been estimated that 22–54% of pregnancies [9, 10] are exposed to prescription medications, excluding vitamins and minerals, during this time period. As a result, the lack of information in relation to the safety of medication during human pregnancy is a serious public health problem [11].

Typically, eligibility criteria for premarketing clinical trials exclude high risk individuals such as pregnant women [12]. The evaluation of medication safety in human pregnancy therefore relies on post-marketing surveillance to detect medication safety signals [13]. As defined by the World Health Organisation (WHO), a signal refers to ‘reported information on a possible causal relationship between an adverse event and a medication, the relationship being unknown or incompletely documented previously’ [14].

Signals are detected when the observed number of reports is higher than expected for a particular medication-event combination [12, 15]. Such statistical signals are frequently found because of the large number of comparisons made and do not necessarily mean that a causal association is present [12]. Even strong signals can be generated by various

forms of confounding [16], so once a signal is generated, signal strengthening and signal evaluation are necessary in order to reinforce or refute the potential signal [13, 16, 17]. While information on true medication safety signals should not be withheld from physicians and patients, false positive signals may cause substantial harm if they limit access to safe medications [17].

Traditionally signal detection has relied on national or international spontaneous reporting systems which pool reports of adverse medication events provided by healthcare providers, consumers and medication manufacturers [15]. Spontaneous report databases have a number of limitations such as under-, over- and duplicate reporting, limited information on concomitant medication or comorbidities and susceptibility to bias [12–14]. To overcome some of these limitations, programmes have been initiated to make use of large data pools besides spontaneous reports such as healthcare databases and disease registries [13, 18, 19]. EUROmediCAT’s population-based reproductive pharmacovigilance system is based on the European Surveillance of Congenital Anomalies (EUROCAT) network. A statistical signal detection analysis was conducted using the EUROmediCAT central database to find highly statistically significant CA-medication exposure associations [20]. The aim of this paper is to describe the protocol used for evaluation of the signals produced by the EUROmediCAT statistical signal detection analysis, and to give the results of evaluation of 27 CA-medication exposure associations to determine which should be prioritized for further investigation. We do not report here signals belonging to four medication groups which were separately investigated as part of the EUROmediCAT project: antiepileptic medications, insulin/insulin analogues, antiasthmatic medications and selective serotonin reuptake inhibitors and psycholeptics [21–24].

Methods

Dataset and statistical signal detection analysis

EUROCAT registries record all cases of major CA seen, among live births, fetal deaths ≥ 20 weeks' gestation and termination of pregnancy for fetal anomaly (TOPFA) [25–27]. Births from 15 EUROmedICAT registries across 13 countries (1995–2011) were used to create a signal detection dataset (see Supplementary Table 1 [20]). This included 14,950 infants with a CA, excluding genetic conditions¹ or isolated congenital dislocation of the hip, who were exposed to a medication in the first trimester, excluding folic acid, minerals, vitamins and/or topical medication [20], coded to the Anatomic Therapeutic Chemical (ATC) classification system [28]. Data on maternal medication exposures are mostly obtained from prospectively recorded maternity records [29, 30].

The signal detection methodology used has been described elsewhere [20]. In brief, a case-malformed control approach was used where cases of a specific CA subgroup [31] were compared with all other CAs in terms of exposure to each specific medication. The signal detection analysis was conducted using medications recorded at the 4th ATC level (chemical subgroup) and the 5th ATC level (chemical substance). Use of different ATC codes for the same medication and changes to ATC codes over time were taken into account. Medications with less than three exposed fetuses/babies were excluded from the analysis. Any registry with no exposures to the medication of interest, or cases of the CA of interest, were also removed from each analysis. Overall, 59 CA subgroups and 693 medication groups were tested, resulting in 40,385 analyses. In order to limit the number of false positive associations, multiple testing procedures were implemented, using a 50% false discovery rate (FDR), where the cut-off *P*-value for associations at the 5th ATC level was 0.00040 and at the 4th ATC level was 0.0011 [20]. As the individual medications at the 5th ATC level all contribute to the 4th ATC level group, if an association arose at both the 4th and 5th ATC levels, the 5th ATC level association was taken as the result. This analysis produced 11 CA-medication exposure signals [20] which were from medication groups not already being investigated as part of the EUROmedICAT project [32], i.e. excluding antiepileptics, anti-diabetics, antiasthmatics and SSRIs/psycholeptics.

A previous analysis of the same dataset without some of the analytic refinements reported here (such as the amalgamation of duplicate ATC codes) [33], and cut-off *P*-values for associations at the 5th and 4th ATC levels of 0.00048 and 0.0028 respectively, had identified an additional 16 signals. These original signals were included for further analysis as a comparison of the odds ratios (OR) and 95% CIs remained very similar between the original and revised analyses (Figure 1 and Table 1), and although the FDR *P*-value threshold was slightly higher, it is not the sole criterion for identifying a potential association of interest. When both sets of results were combined, there were 27 CA-medication exposure signals. Results are given combined and separately.




Figure 1

Signal evaluation flow diagram

Signal validation

Initially, the exposed cases for each of the 27 CA-medication exposure associations were validated, in terms of diagnosis, medication exposure and timing of exposure, with the local registries.

The OR based on these validated data were then adjusted for confounding by registry, i.e. where a registry may differ in both their (recorded) exposure proportion and (recorded) CA subgroup proportion in such a way as to produce artificial relationships between the exposure and outcome. Adjustment for registry was done by conducting a meta-analysis in STATA/SE 12.1 using the fixed effect Mantel-Haenszel method [34, 35]. Continuity corrections were made as per the method by Sweeting et al. [36].

With the exception of chromosomal anomalies, most CAs are not strongly associated with maternal age [37]. However, gastroschisis, an abdominal wall defect, is associated with young maternal age [38] and it was necessary to adjust the gastroschisis-medication exposure association for maternal age. This was done by stratifying the meta-analysis by maternal age group [39], categorized as <20, 20–24, 25–29, 30–34, 35–39 and 40+.

Those CA-medication exposure associations which persisted, when using validated data and adjusting for registry effects, were considered validated statistical signals.

Signal description

The validated statistical signals were then described in detail in terms of the signal ORs and 95% CIs, the adjusted ORs and 95% CIs using validated data, the number of exposed cases and the most prevalent concurrent medication

¹Chromosomal anomalies, genetic syndromes and skeletal dysplasias

Table 1

Description of validated signals

ATC code/s Medication/s and congenital anomaly	Signal OR (95% CI)	P value	Number of cases (confirmed 1st trimester exposures)	Mantel-Haenszel adjusted* OR using validated data (95% CI)	Most prevalent concurrent medication exposures among cases (n)	Significant positive medication-CA exposure associations not meeting FDR criteria (unvalidated†)
A02AD01 Ordinary salt combinations and cleft lip with or without cleft palate	2.38 (1.46–3.72)	0.00036	23 (21)	1.70 (1.06–2.72)	None (4), piperazine derivatives R06AE(2), other medications for peptic ulcer and gastro-oesophageal disease (2), paracetamol N02BE01 (2), cisapride A03AF02 (1)	A02AD01 and cleft palate (OR 2.65, 95% CI 1.49–4.42) A02AD01 and Anophthalmos/microphthalmos (OR 5.17, 95% CI 1.57–13.35) A02AB04 and polydactyly (OR 16.62, 95% CI 2.20–124.82)
A03FA Propulives (metoclopramide, cisapride, domperidone, bromopride, alizapride, clebopride and itopride) and total anomalous pulmonary venous return‡	6.41 (1.89–17.46)	0.0021	5 (5)	10.49 (3.45–31.93)	None (10), levothyroxine sodium H03AA01 (2), omeprazole A02BC01 (1), prochlorperazine N05AB04 (1), promethazine R06AD02 (1)	None
A06AC Bulk-forming laxatives (ispaghula (psylla seeds), ethulose, sterculia, linseed, methylcellulose, tritcum (wheat fibre), polycarbophil calcium, ispaghula combinations, sterculia combinations and linseed combinations) and anencephalus and similar‡	8.98 (2.29–25.53)	0.0015	4 (4)	6.38 (2.23–18.24)	None (2), amoxicillin J01CA04 (1), follitropin alfa G03GA05 (1), chorionic gonadotrophin G03GA01 (1), levonorgestrel and ethinylestradiol G03AA07 (1)	A06AC and ventricular septal defect (OR 2.69, 95% CI 1.34–5.21) A06AC and cleft lip with or without cleft palate (OR 3.37, 95% CI 1.16–8.10) A06AC and neural tube defects (OR 3.64, 95% CI 1.11–9.32) A06AD and club foot/talipes equinovarus (OR 2.21, 95% CI 1.09–4.09)
A07DA Antipropulives (diphenoxylate, opium, loperamide, diffenoxin, loperamide oxide, morphine combinations and loperamide combinations) and syndactyl‡	10.12 (2.42–32.05)	0.0013	4 (4)	6.41 (2.28–18.00)	None (3), nitrofurantoin J01XE01 (1)	None
C02DB Hydrazinophthalazine derivatives (dihydralazine, hydralazine, endralazine, cadralazine) and Atrial septal defect (ASD)‡	5.78 (1.39–22.81)	0.0077	5 (5)	2.78 (1.07–7.24)	None (3), methyl dopa C02AB01 (2), diprophylline R03DA01 (1)	None
G03AB03 or G03AA07 Levonorgestrel and ethinylestradiol and gastroschisis‡	4.10 (1.70–8.53)	0.0013	8 (8)	2.95 (1.38–6.33)§	None (6), trimethoprim J01EA01 (1), ibuprofen M01AE01 (1)	G03AB03 or G03AA07 and bladder extrophy and/or epispadia (OR 7.05, 95% CI 1.36–23.2) G03AA09 and neural tube defects (OR 4.88, 95% CI 1.23–14.18)

(continues)

Table 1

(Continued)

ATC code/s Medication/s and congenital anomaly	Signal OR (95% CI)	P value	Number of cases (confirmed 1st trimester exposures)	Mantel-Haenszel adjusted* OR using validated data (95% CI)	Most prevalent concurrent medication exposures among cases (n)	Significant positive medication-CA exposure associations not meeting FDR criteria (unvalidated†)
G03DA Pregnen (4) derivatives (gestonorone, medroxyprogesterone, hydroxyprogesterone and progesterone) and complete absence of a limb‡	6.60 (1.70–22.93)	0.0035	5 (5)	7.60 (2.34–24.67)	None (3), estradiol combinations G03CA53 (1), estradiol G03CA03 (1)	G03AA13 and CHD (OR 6.12, 95% CI 1.16–60.46) G03AA and congenital cataract (OR 3.47, 95% CI 1.09–8.54) G03AA and anencephalus and similar (OR 2.69, 95% CI 1.05–5.76)
G03DB Pregnen derivatives (dydrogesterone, megestrol, medrogestone, norgestrol, demegestone, chlormadinone, promegestone and dienogest) and hypospadias‡	1.40 (1.10–1.76)	0.0036	91 (89)	1.51 (1.15–1.98)	None (59), drotravine A03AD02 (7), hydroxyprogesterone G03DA03 (6), aspirin B01AC06 (4), progesterone G03DA04 (3), A03AD02 (5)	G03DA04 and ASD (OR 1.38, 95% CI 1.12–1.68) G03DC and ASD (OR 1.79, 95% CI 1.09–2.82) G03DC and neural tube defects (OR 2.21, 95% CI 1.07–4.13) G03DC and limb reduction (OR 2.26, 95% CI 1.00–4.47)
G03CB Synthetic ovulation stimulants (cyclofemil, clomiphene and epimestrol) and hypospadias	1.89 (1.28–2.70)	0.00073	37 (36)	1.92 (1.35–2.74)	None (22), progesterone G03DA04 (4), chorionic gonadotropin G03GA01 (4), levothyroxine sodium H03AA01 (3), labetalol C07AG01 (2)	G03CA and laterality (OR 4.92, 95% CI 1.72–11.47) G03CA08 and ASD (OR 1.95, 95% CI 1.21–3.02) G03CA01 and congenital constriction bands/amniotic band (8.00, 95% CI 1.53–26.59) G03CA02 and neural tube defects (OR 3.12, 95% CI 1.19–6.98) G03CA04 and ventricular septal defect (OR 7.34, 95% CI 1.24–50.14) G03CA01 and bladder exstrophy and/or epispadia (OR 6.45, 95% CI 1.25–20.97)
L02AE Gonadotropin releasing hormone analogues (buserelin, leuprorelin, goserelin, triptorelin and histrelin) and laterality anomalies‡,¶	13.34 (2.52–45.08)	0.0021	3 (3)	9.09 (2.75–30.08)	follitropin alfa G03GA05 (2), chorionic gonadotropin G03GA01 (2), urofollitropin G03GA04 (1), progesterone G03DA04 (1)	L02AE04 and severe CHD (OR 4.52, 95% CI 1.01–16.3)

(continues)

Table 1

(Continued)

ATC code/s Medication/s and congenital anomaly	Signal OR (95% CI)	P value	Number of cases (confirmed 1st trimester exposures)	Mantel-Haenszel adjusted* OR using validated data (95% CI)	Most prevalent concurrent medication exposures among cases (n)	Significant positive medication-CA exposure associations not meeting FDR criteria (unvalidated†)
J05AF Nucleoside and nucleotide reverse transcriptase inhibitors (zidovudine, didanosine, zalcitabine, stavudine, lamivudine, abacavir, tenofovir disoproxil, adefovir dipivoxil, emtricitabine, entecavir, telbivudine, clevudine) and congenital heart defects (CHD)	5.01 (1.99–14.2)	0.00012	18 (20)**	2.04 (1.17–3.55)**	None (8), protease inhibitors J05AE (8), ritonavir J05AE03 (4), lopinavir and ritonavir J05AE06 (3), sulfamethoxazole and trimethoprim J01EE01 (1), combinations of sulfonamides and trimethoprim, including derivatives J01EE (1)	J05AF and severe CHD (OR 3.53, 95% CI 1.15–9.22) J05AB11 and polydactyly (OR 7.69, 95% CI 1.38–28.46) J05AE03 and CHD (OR 5.92, 95% CI 1.05–60.21)
J05AF30 Combinations of nucleoside and nucleotide reverse transcriptase inhibitors and pulmonary valve stenosis	28.2 (4.63–122.24)	0.00039	3 (4)**	5.08 (1.83–14.07)**	Nucleoside and nucleotide reverse transcriptase inhibitors J05AF (3), protease inhibitors J05AE (2), nevirapine J05AG01 (1), non-nucleoside reverse transcriptase inhibitors J05AG (1), lopinavir and ritonavir J05AE06 (1), saquinavir J05AE01 (1)	J05AF30 and ASD (OR 6.08, 95% CI 1.03–25.55)
N02CC Selective serotonin (5HT1) agonists (sumatriptan, naratriptan, rizatriptan, almotriptan, eletriptan and frovatriptan) and congenital constriction bands/amniotic band‡	12.97 (2.46–43.53)	0.0022	3 (3)	15.58 (4.44–54.62)	ispaghula A06AC01 (1), 'other' anti-obesity medications A08AX (1), dalteparin B01AB04 (1), fluconazole J02AC01 (1), ibuprofen M01AE01 (1)	N02CC and encephalocele (OR 6.12, 95% CI 1.20–19.38) N02CC and pulmonary valve atresia (OR 5.25, 95% CI 1.04–16.48) N02CC05 and ASD (OR 11.99, 95% CI 1.6–89.73) N02CC06 and club foot/talipes equinovarus (OR 8.59, 95% CI 1.33–44.29)

More detail is provided than usual for P-values due to the number of decimal places of relevance to the interpretation of the signal detection results. *Using validated data and adjusting for registry.

†Not validated in terms of CA or medication exposure and not adjusted for registry. ‡Signal from original analysis not meeting revised FDR P-value threshold. §Adjusted for maternal age category.

¶Laterality group includes atrial isomerism, dextrocardia, situs inversus, broncho-pulmonary isomerism, asplenia and polysplenia. **Includes J05AX04, J05AB05, J05AB07, J05AB08, J05AB10, J05AF, J05AF01–12, J05AF30, J05AR01–09 and J05AR11–13 in adjusted analysis due to changes over time in the ATC coding of Ns/NTRTs (including in combination).

exposures recorded among exposed cases. In addition, the statistically significant CA-medication exposure associations which failed to meet the FDR threshold (FDR <50%) but which involved the same medication, or 3rd ATC level, exposure were also noted.

Signal literature review

A literature review was then conducted, for the validated statistical signals, by searching REPROTOX, TOXBASE, the Developmental and Reproductive Toxicology Database (DART) and PubMed. For those signals at the 5th ATC level, this involved searching initially for the specific medication and then for the 4th ATC level medication group. For signals at the 4th ATC level a literature review was conducted for both the medication group and each specific medication in the group. REPROTOX and TOXBASE were searched using the medication/group name alone. DART and PubMed were searched using the name of the medication/group combined with search terms for teratogen and CA (see Supplementary Document 1 for more detail). The reference lists of relevant articles were also searched. Cohort and case-control studies were of particular interest but case reports/series were also noted where available as the evidence was limited for some medications. The available published evidence was categorized according to the amount of evidence to support the signal in the human literature, i.e. signal CA described in the literature, teratogenicity leading to other CA described in the literature, or no evidence of teratogenicity in the literature. When the evidence was based on case reports/series or a single case-control or cohort study, the published evidence was noted as minimal.

Ethical approval

Ethical approval for this study was provided by the University of Ulster Nursing Research Governance Filter Committee.

Results

Signal validation

Out of the 27 original CA-medication exposure associations 14 (seven from the original and seven from the revised analysis) were not validated as independent signals: one was a duplicate signal as more than one formulation of the medication is available (the combined contraceptive levonorgestrel and ethinylestradiol); for five CA-medication exposure associations a proportion of the CA cases and/or first trimester medication exposures could not be verified so that the OR using validated data more than halved to less than 1.5; eight CA-medication exposure associations were explained by confounding by registry.

This left 13 (nine from the original and four from the revised analysis) validated unique CA-medication exposure signals related to gastrointestinal medications ($n = 4$), antihypertensives ($n = 1$), female sex hormones ($n = 3$), medications used in infertility treatments ($n = 2$), antiretrovirals ($n = 2$) and selective serotonin (5HT1) agonists ($n = 1$).

Signal description

The 13 statistical signals were based on between three and 89 confirmed CA cases with first trimester medication exposures (Table 1).

Signal literature review

Of the 13 validated signals for which a literature review was conducted, previous evidence in the literature was found for six (Table 2).

Discussion

We have found 13 CA-medication exposure signals which require further confirmation. There was evidence in the literature, albeit conflicting at times, to support six of the 13 signals [40–64]. These six signals have been strengthened and should be prioritized for further evaluation. Four of these signals were related to sex hormones (gastroschisis and the contraceptive levonorgestrel/ethinylestradiol; complete absence of a limb and pregnen (4) derivatives; hypospadias and pregnadien derivatives; hypospadias and synthetic ovulation stimulants). We also had as yet unvalidated data that some other anomalies might be associated with these medications. Sex hormone-based medications accounted for 24.8% of the medication exposures in the database [20]. The other two of these signals were congenital heart defects and pulmonary valve stenosis associated with nucleoside/nucleotide reverse transcriptase inhibitors, antivirals used for HIV and chronic hepatitis. For all of these signals, the possibility of confounding by indication, or by co-exposures, should be considered. The progestogens are used to 'support' pregnancies at risk of early loss. It may be that this leads to increasing survival of CA-affected fetuses [65]. Sub-fertile women have been found to have a higher risk of having a child with a CA regardless of whether or not they receive infertility treatment [66–69], and this or other co-exposures may confound the interpretation of medication use related to subfertility or infertility [69]. Those receiving antiviral treatment for HIV or hepatitis infection may have other exposures leading to an increased risk of CAs [70]. However, the case-malformed control approach used in this study will have negated this issue to some extent as the comparison group also have CAs.

The only evidence that the antipropulsive antidiarrheals may be teratogenic was a single report of an association with hypospadias [71], rather than syndactyly as in our results. These two anomalies are usually considered aetiologically unrelated.

The remaining six statistical signals did not have supporting evidence in the literature and should be confirmed in an independent dataset. For selective serotonin agonists, a number of previous studies have found no association with CA [72–81] but these were too small to find an anomaly as rare as congenital constriction bands. Hydrazinophthalazine derivatives, antihypertensives which act on arteriolar smooth muscle, have one small previous negative study [82]. Other types of antihypertensives, such as ace inhibitors, have been associated with an increased risk of CA [83] but the underlying maternal hypertension also appears to play a role in the development of CA [84].

Table 2

Results of literature review relating to 13 validated signals

Signal	Evidence to support signal	Medication uses and literature relating to their teratogenicity in humans
A02AD01 Ordinary salt combinations Cleft lip with or without cleft palate	C**	Ordinary salts are combinations and complexes of aluminium, calcium and magnesium compounds used as antacids. There is no evidence relating specifically to the teratogenicity of the ordinary salt combinations. One case-control study explores the teratogenicity of combinations and complexes of aluminium, calcium and magnesium. No increase in all CAs combined among those treated with aluminium magnesium hydroxide (OR 1.5, 95% CI 0.3–8.9) or aluminium magnesium hydroxide (OR 0.6, 95% CI 0.2–2.4) was reported [103].
A03FA Propulsives (metoclopramide, cisapride, domperidone, bromopride, alzapride, clebopride and itopride) Total anomalous pulmonary venous return	C	Propulsives enhance gastrointestinal motility and are used to treat nausea and vomiting. Cohort studies have found no increase in the risk of all CAs combined [90–94], hypospadias or orofacial clefts [95] following exposure to the propulsives. There was no evidence of an association between transposition of the great vessels, ventricular septal defect (VSD), atrial septal defect (ASD), Tetralogy of Fallot, pulmonary valve stenosis or coarctation of the aorta [96] and first trimester exposure to metoclopramide (A03FA01). A retrospective cohort study found no significant association between first trimester exposure to metoclopramide and ‘other anomalies of the circulatory system’, a group which includes total anomalous pulmonary venous return [97]. However, the number of cases involved in this group was small and it is unclear what proportion, if any, had total anomalous pulmonary venous return. No studies have looked specifically at the risk of total anomalous pulmonary venous return.
A06AC Bulk-forming laxatives (ispaghula (psylla seeds), ethulose, sterculia, linseed, methylcellulose, triticum (wheat fibre), polycarbophil calcium, ispaghula combinations, sterculia combinations and linseed combinations) Anencephalus and similar anomalies	C**	Bulk-forming laxatives are used to treat constipation. The single cohort study exploring the teratogenicity of ispaghula (A06AC01) found no significant difference in the rate of all CAs combined between those who were exposed in the first trimester and those who were not [104].
A07DA Antipropulsives (diphenoxylate, opium, loperamide, difenoxin, loperamide oxide, morphine combinations and loperamide combinations) Syndactyly	B	Antipropulsives are used to treat diarrhoea. Two cohort studies explore the teratogenicity of loperamide (A07DA03) and found no increase in all CAs combined [105]. An association was found between loperamide exposure and hypospadias (RR 3.2, 95% CI 1.3–6.6, $n = 7$) but multiple comparisons mean that this may have been due to chance [71].
C02DB Hydrazinophthalazine derivatives (dihydralazine, hydralazine, endralazine, cadralazine) Atrial septal defect (ASD)	C**	Hydrazinophthalazine derivatives act on arteriolar smooth muscle and are used to treat hypertension. A single case-control study found no significant association between dihydralazine (C02DB01) exposure, before and throughout pregnancy, and all CAs combined [82].
G03AB03/G03AA07 Levonorgestrel and ethinylestradiol Gastrostschisis	A	Levonorgestrel and ethinylestradiol is a combined oral contraceptive containing both an oestrogen and a progestogen. Evidence specifically relating to levonorgestrel and ethinylestradiol is limited to one large case-control study where 6/133 (4.5%) CA case and 8/129 (6.2%) non-malformed control infants were exposed to levonorgestrel and ethinylestradiol [106]. Exposure to oral contraceptives in early pregnancy does not increase the risk of all CAs combined [107, 108], neural tube defects (NTD) [109–111], CHD [108] or orofacial cleft [112]. The evidence relating to gastrostschisis is conflicting with some articles showing a significant association (68% of gastrostschisis cases exposed vs. 26% of malformed controls [40]; OR 1.8, 95% CI 1.3–2.7, $n = 40$ [41]) and others showing none [42, 43]. The same is true for genital anomalies [44, (continues)

Table 2
(Continued)

Signal	Evidence to support signal	Medication uses and literature relating to their teratogenicity in humans
G03DA Pregnen (4) derivatives (gestonorone, medroxyprogesterone, hydroxyprogesterone and progesterone) Complete absence of a limb	A	45, 113–116]. One case-control study describes an increased risk of urinary tract anomalies following first trimester exposure to oral contraceptives [117]. Pregnen (4) derivatives are progestogens, compounds with biological activity similar to progesterone, used in hormone replacement therapy, infertility and to treat menstrual problems. Cohort and case-control studies found no significant increase in all CAs combined with any of the progestogens [118–124]. A cohort study found that medroxyprogesterone (G03DA02) increases the rate of CHDs, gastro-intestinal defects, CAs of the integument, chromosome defects and all other defects. These findings may be due to chance as multiple comparisons were made and the range of defects including chromosomal defects is not plausible [125]. A number of case-control studies have found a significant association between hypospadias and both hydroxyprogesterone (G03DA03) and progesterone (G03DA04) [46, 126, 127]. However, other studies have found no association [44, 47, 128] and recall bias is a concern [48]. In the 1960s and 1970s a number of studies were published linking 'sex hormones' with an increased incidence of nongenital congenital malformations such as CHDs and limb reduction defects [49–55]. However, the evidence supporting the link between progestogens and contraceptive agents with nongenital malformations was contradictory, poor methodologically and the study material lacked uniformity [121, 129, 130]. By 1993 the controversy surrounding this issue meant that there had been 20 review articles written on this subject, none of which concluded that sex hormones produced nongenital organ teratogenesis [56, 57].
G03DB Pregnadien derivatives (dydrogesterone, megestrol, medrogestone, nomegestrol, demegestone, chlormadinone, promegestone and dienogest) Hypospadias	A	Pregnadien derivatives are also progestogens and are used as per the pregnadien derivatives. A review of case reports and three very small trials found no increase in all CAs combined with dydrogesterone (G03DB01) [131–134]. The broader medication group, the progestogens, have been associated with hypospadias [45, 47, 58] but these findings have not been consistent [44, 46, 48, 59].
G03GB Synthetic ovulation stimulants (cyclofemil, clomiphene and epimestrol) Hypospadias	A	Synthetic ovulation stimulants are used in infertility treatment. Across cohort and case-control studies there is no evidence that exposure to clomiphene citrate (G03GB02) in the periconceptual period increases the rate of all CAs combined. There is conflicting evidence of an association with NTDs [135–137]. Clomiphene has been associated with coarctation of the aorta [66, 138], anencephaly, Dandy Walker malformation, septal heart defects, muscular ventricular septal defects, esophageal atresia, cloacal extrophy, craniosynostosis and omphalocele but multiple comparisons and small numbers of cases make these findings tentative [66]. An association between periconceptual clomiphene exposure and the more severe, proximal forms of hypospadias [44, 60–62], but not all forms of hypospadias combined [63, 64], has been described.
L02AE Gonadotropin-releasing hormone analogues (GnRHα) (buserelin, leuprorelin, goserelin, triptorelin and histrelin) Laterality	C**	Gonadotropin-releasing hormone analogues are used in infertility treatment. Evidence relating to the teratogenicity of the GnRHα's is limited to case reports/series [86–89]. There is no evidence for a pattern of anomalies but the numbers reported are small and there is potential for reporting bias.
J05AF Nucleoside and nucleotide reverse transcriptase inhibitors (Ns/NRTIs) (zidovudine, didanosine, zalcitabine, stavudine, lamivudine, abacavir, tenofovir disoproxil, adefovir dipivoxil, emtricitabine, entecavir, telbivudine, clevudine) Congenital heart defects (CHD)	A	The Ns/NRTIs are used to treat HIV/AIDS and chronic hepatitis. Case-control, cohort studies and a manufacturer maintained pregnancy registry explore the teratogenicity of individual Ns/NRTIs and the group as a whole. There is no evidence that first trimester exposure to any of the individual Ns/NRTIs, or the group as a whole, increases the rate of all CAs combined [139–143]. First trimester exposure to zidovudine (J05AF01) has been found to increase the risk of CHD [143, 144], but this has not been a consistent finding [145, 146]. A significant association between first trimester exposure to ARV regimes containing at least one Ns/NRTI and CHD is reported [147]. There is no evidence relating to the risk of PVS as a specific CHD. Small numbers of cases have also suggested an increased risk of central nervous system (CNS) anomalies [146] and hypospadias [148] following first trimester exposure to zidovudine and head and neck defects following first trimester exposure to didanosine (J05AF02) [143].

(continues)

Table 2

(Continued)

Signal	Evidence to support signal	Medication uses and literature relating to their teratogenicity in humans
J05AF30 Combinations of nucleoside and nucleotide reverse transcriptase inhibitors Pulmonary valve stenosis (PVS)	A	
N02CC Selective serotonin agonists (sumatriptan, naratriptan, rizatriptan, almotriptan, eletriptan and frovatriptan) Congenital constriction bands or amniotic bands	C	Selective serotonin agonists, also called triptans, are used to treat migraines. Cohort studies and a manufacturer maintained pregnancy registry explore the teratogenicity of these medications, sumatriptan (N02CC01) in particular. First trimester exposure to sumatriptan does not significantly increase the rate of all CAs combined [72–77]. Eletriptan (N02CC06) was found to significantly increase the rate of all CAs combined but this was based on 14 exposures and may have been a chance finding [78]. None of the other triptans [75, 77, 79], or the triptans as a group appear to increase the rate of all CAs combined [76, 80, 81].

A: teratogenicity leading to signal CA described in literature; B: teratogenicity leading to other CA described in literature; C: no evidence of teratogenicity. *Published evidence minimal

While there are concerns about assisted reproduction in general in relation to CA risk [85], and two of our other signals discussed above are medications used in assisted reproduction, there is only minimal case report evidence [86–89] relating to gonadotropin releasing hormone analogues, and none of these case reports relate to laterality anomalies. Previous studies of the pro-pulsives [90–97] have been negative regarding teratogenicity and there is no evidence to support our finding. The ordinary salts and bulk-forming laxatives are generally assumed to be safe, have low bioavailability, do not interfere with normal physiologic salt balance and therefore were not specifically studied.

The signal detection methodology used in EUROmediCAT was based on a 50% FDR. This means that half of the associations found are expected to be chance associations, i.e. not causal. Due to this uncertainty, and the difficulties of interpretation discussed above, medication decisions should not be made based on the CA-medication exposure signals identified but should await the results of further research.

Strengths and limitations

A strength of this study is the use of the EUROmediCAT central database. EUROmediCAT's international population-based database contains detailed coding of all CAs [29] and includes TOPFA cases which constitute a large proportion of some CA [98]. The diagnosis of CAs is standardized across the registries involved and will have ensured consistency in the diagnosis [27]. There will also be much less under-reporting and bias than in spontaneous reporting pharmacovigilance systems as all major CAs are recorded in EUROCAT, not just those which clinicians consider to be important enough or potentially linked to a medication exposure. While the EUROmediCAT database contains detailed information on medications taken during the first trimester of pregnancy, there is known underascertainment of some medications [30, 99] but while this may reduce the sensitivity of the system to detect certain teratogenic medications, it should not lead to bias due to the use of malformed controls.

It was only possible to validate the data relating to the exposed cases. This means that while the number of exposed cases may have decreased, owing to errors found in data coding, the number of exposed controls will not have changed. As a result, the data validation process could only decrease the ORs. We found evidence that other anomalies were also associated with the signal medications, but at lower levels of statistical significance which did not surpass the FDR threshold, and did not validate these data. However, data validation for the main findings is a strength of this study.

The signal detection process used did not take prior literature into account during the statistical analysis [100] but instead brought this in at the signal evaluation stage. In the EUROmediCAT analyses of antiepileptics, antidiabetics, antidepressants and antiasthmatics [21–24], we first searched the literature before evaluating existing signals and detecting new signals. The signal detection process we report in this paper is intended to be used in addition to the drug class by drug class approach. It can be used to identify the most highly significant associations in the database for drug classes not otherwise undergoing analysis. We recognize that there may be many other associations in the data that did not meet

the FDR threshold but which are nevertheless of potential interest. Indeed, this is shown by our evaluation of the 16 signals arising from the original signal detection analysis, which included a number of associations reported previously in the literature.

While the literature search was extensive, it is possible that relevant articles may have been missed, particularly negative evidence for a medication exposure when analysed as one of many aetiological factors in a case-control study. We were assessing whether previous literature existed but did not conduct a meta-analysis of the evidence to date, and this may lead to highlighting positive over negative evidence, although all evidence found is presented. It was necessary to search for each of the individual medications, rather than the broader medication group, as the 4th ATC level, chemical subgroup, was not always used in the literature or databases and returned little or no information for some of the signals. Without prior hypotheses about the mechanism of action, it can also be difficult to decide how broadly to look for related literature – for example there is a large literature on sex hormones as a class, but much less related to specific sex hormones. While positive evidence in the literature regarding risk of all CAs combined could be considered supportive, negative evidence is more difficult to interpret, as few medications increase the rate of all CAs combined, instead tending to increase the rate of specific CAs [101].

As far as possible, changes over time in the ATC codes used for particular medications were taken into account in both the signal detection analysis and the signal evaluation. It is possible, however, that some changes were missed, potentially leading to signals being missed as the exposed cases would be split across more than one ATC code in the dataset.

Although all the cases were confirmed as first trimester exposures, it is not known if these exposures actually occurred during the critical period for CA development [8]. Similarly there was no information available in terms of the doses of medications taken for the majority of cases. If it was possible to identify a dose–response relationship or show exposure during the critical period for development of the specific CAs, this would provide support for a causal relationship [101]. Our protocol did not include assessment of biological plausibility or possible teratogenic mechanisms [102]. Although grouping of CA or of medications by potential teratogenic mechanism has been advocated [3], we found this to be of limited use as the same CAs are often related to a number of potential mechanisms, and the current imperfect knowledge of mechanisms is one of the drivers of signal detection in postmarketing surveillance.

Conclusion

A statistical signal detection analysis was conducted using the EUROmediCAT central database. Six signals had some prior supporting evidence and these should be prioritized for further investigation before being evaluated in relation to clinical decision making. A further seven CA-medication exposure signals were found which had no prior supporting evidence and these need to be confirmed in independent datasets.

Contributors

JEG performed statistical analysis of the signals, literature review and drafted the manuscript. JML and JM performed the statistical signal detection analysis on which this article is based and advised on the interpretation of the results. ML advised on the conduct and co-ordination of the study as well as interpretation of the results. LJB and EG advised on interpretation of the results. EG, MCA, IB, HdeW, MG, KK, BK, AL-B, VN, AJN, MO'M, AP, DT and AW provided and verified the data. HD participated in the design, conduct and coordination of the study, advised on interpretation of the results and critically revised the manuscript. HD and LJB wrote the funding application. All authors, commented on drafts, read and approved the final manuscript.

Competing Interests

All authors have completed the Unified Competing Interest form at http://www.icmje.org/coi_disclosure.pdf (available on request from the corresponding author) and declare: The study was funded by the European Commission under the 7th Framework Program (grant agreement HEALTH-F5-2011-260598). AP received grants from the Institute of Clinical Physiology-National Research Council (IFC-CNR) during the conduct of the study for the submitted work. The institutions of HD, ML, JM, EG, MCA, IB, MG, BK, AL-B, VN, AJN, MO'M, AP, DT and AW received funding from Glaxo Smith Kline (GSK) outside the submitted work in the previous 3 years. There are no other relationships or activities that could appear to have influenced the submitted work.

EUROCAT registries are funded as fully described in Paper 6 of Report 9 – EUROCAT Member Registries: Organization and Activities, available at <http://onlinelibrary.wiley.com/doi/10.1002/bdra.20775/pdf>.

We thank the people throughout Europe involved in providing and processing information, including affected families, clinicians, health professionals, medical record clerks and registry staff.

References

- 1 WHO/CDC/ICBDSR. Birth Defects Surveillance: Atlas of Selected Congenital Anomalies. Geneva: World Health Organization, 2014.
- 2 EUROCAT. EUROCAT: European Surveillance of Congenital Anomalies [online]. Available at <http://www.eurocat-network.eu/> (last accessed 18 April 2016).
- 3 van Gelder MMHJ, van Rooij IALM, Miller RK, Zielhuis GA, de Jong-van den Berg LTW, Roeleveld N. Teratogenic mechanisms of medical drugs. *Hum Reprod Update* 2010; 16: 378–94.
- 4 World Health Organization. Fact sheet No. 370 Congenital anomalies [online]. Available at <http://www.who.int/mediacentre/factsheets/fs370/en/> (last accessed 18 April 2016).
- 5 World Health Organization. Birth defects: report by the Secretariat [online]. Geneva: WHO, 2010. Available at http://apps.who.int/gb/ebwha/pdf_files/WHA63/A63_10-en.pdf?ua=1 (last accessed 18 April 2016).

- 6 Koren G, Pastuszak A, Ito S. Drugs in pregnancy. *N Engl J Med* 1998; 338: 1128–37.
- 7 Mitchell AA, Gilboa SM, Werler MM, Kelley KE, Louik C, Hernández-Díaz S. Medication use during pregnancy, with particular focus on prescription drugs: 1976–2008. *Am J Obstet Gynecol*. 2011; 205: 1–17.
- 8 Czeizel AE. Specified critical period of different congenital abnormalities: a new approach for human teratological studies. *Congenit Anom (Kyoto)* 2008; 48: 103–9.
- 9 Daw JR, Hanley GE, Greyson DL, Morgan SG. Prescription drug use in pregnancy in developed countries: a systematic review. *Pharmacoepidemiol Drug Saf* 2011; 20: 895–902.
- 10 Lupattelli A, Spigset O, Twigg MJ, Zagorodnikova K, Mårdby AC, Moretti ME, *et al.* Medication use in pregnancy: a cross-sectional, multinational web-based study. *BMJ Open* 2014; 4: e004365.
- 11 Adam MP, Polifka JE, Friedman JM. Evolving knowledge of the teratogenicity of medications in human pregnancy. *Am J Med Genet Part C Semin Med Genet* 2011; 157: 175–82.
- 12 Sharrar RG, Dieck GS. Monitoring product safety in the postmarketing environment. *Ther Adv Drug Saf* 2013; 4: 211–9.
- 13 Suling M, Pigeot I. Signal detection and monitoring based on longitudinal healthcare data. *Pharmaceutics* 2012; 4: 607–40.
- 14 Eduards IR, Biriell C. Harmonisation in pharmacovigilance. *Drug Saf* 1994; 10: 93–102.
- 15 Hauben M, Reich L. Potential utility of data-mining algorithms for early detection of potentially fatal/disabling adverse drug reactions: a retrospective evaluation. *J Clin Pharmacol* 2005; 45: 378–84.
- 16 Hauben M. A brief primer on automated signal detection. *Ann Pharmacother* 2003; 37: 1117–23.
- 17 Schneeweiss S. A basic study design for expedited safety signal evaluation based on electronic healthcare data. *Pharmacoepidemiol Drug Saf* 2010; 19: 858–68.
- 18 Robert E, Vollset SE, Botto L, Lancaster PA, Merlob P, Mastroiacovo P, *et al.* Malformation surveillance and maternal drug exposure: the MADRE project. *Int J Risk Saf Med* 1994; 6: 75–118.
- 19 Trifiro G, Fourrier-Reglat A, Sturkenboom MCJM, Díaz Acedo C, Van Der Lei J. The EU-ADR project: preliminary results and perspective. *Stud Health Technol Inform* 2009; 148: 43–9.
- 20 Luteijn JM, Morris JK, Garne E, Given J, de Jong-van den Berg L, Addor M-C, *et al.* EUROmediCAT signal detection: a systematic method for identifying potential teratogenic medication. *Br J Clin Pharmacol* 2016; 82: 1110–22.
- 21 Wang H, Wender-Ozegowska E, Garne E, Morgan M, Loane M, Latos-Bielenska A, *et al.* Use of insulin analogs in pre-gestational diabetes and risk of congenital anomalies. *Pharmacoepidemiol Drug Saf* 2015; 24 (S1): 10–1.
- 22 Boyle B, Loane M, Bakker MK, Addor MC, Arriola L, Garne E, *et al.* Selective serotonin reuptake inhibitor (SSRI) use in first trimester pregnancy and risk of congenital anomalies: a EUROmediCAT case-malformed control study in 12 countries. *Pharmacoepidemiol Drug Saf* 2015; 24 (S1): 15.
- 23 Garne E, Hansen AV, Morris J, Zaupper L, Addor M-C, Barisic I, *et al.* Use of asthma medication during pregnancy and risk of specific congenital anomalies: a European case-malformed control study. *J Allergy Clin Immunol* 2015; 136: 1496–502.
- 24 Wang H, Loane M, Dolk H, Morris J, Garne E, De Jong-van den Berg LTW, *et al.* Use of topiramate in relation to the risk of orofacial clefts. *Pharmacoepidemiol Drug Saf* 2015; 24 (S1): 11–2.
- 25 EUROCAT Central Registry. EUROCAT Guide 1.1. Instructions for the registration of congenital anomalies [online]. Brussels: EUROCAT, 1990. Available at <http://www.eurocat-network.eu/content/EUROCAT-Guide-1.1-1990.pdf> (last accessed 18 April 2016).
- 26 EUROCAT Central Registry. EUROCAT Guide 1.2. Instructions for the registration of congenital anomalies [online]. Newtownabbey: EUROCAT, 2002. Available at <http://www.eurocat-network.eu/content/EUROCAT-Guide-1.2.pdf> (last accessed 18 April 2016).
- 27 EUROCAT Central Registry. EUROCAT Guide 1.3 and reference documents. Instructions for the registration and surveillance of congenital anomalies. Newtownabbey: EUROCAT, 2005.
- 28 WHO Collaborating Centre for Drug Statistics Methodology. Guidelines for ATC classification and DDD assignment. Oslo: WHO Collaborating Centre for Drug Statistics Methodology, 2014.
- 29 Boyd PA, Haeusler M, Barisic I, Loane M, Garne E, Dolk H. Paper 1: The EUROCAT network-organization and processes. *Birth Defects Res Part A – Clin Mol Teratol* 2011; 91: 2–15.
- 30 Bakker M, de Jonge L. EUROCAT Special Report: Sources of Information on Medication Use in Pregnancy [online]. Newtownabbey: EUROCAT Central Registry, 2014. Available at <http://www.eurocat-network.eu/content/Special-Report-Medication-Use-In-Pregnancy.pdf> (last accessed 18 April 2016).
- 31 EUROCAT Central Registry. EUROCAT Guide 1.4 and Reference Documents [online]. Newtownabbey: EUROCAT, 2013. Available at http://www.eurocat-network.eu/aboutus/datacollection/guidelinesforregistration/guide1_4 (last accessed 18 April 2016).
- 32 de Jong-van den Berg LTW, Bakker MK, Dolk H. EUROmediCAT: European surveillance of safety of medication use in pregnancy. *Pharmacoepidemiol Drug Saf* 2011; 20: S46–7.
- 33 EUROmediCAT. Safety of Medication Use in Pregnancy: European Conference Poznan, Poland, February 2–4, 2015 [online]. Poznan: EUROmediCAT, 2015. Available at <http://euromedicat.eu/content/EUROmediCAT-Poznan-Conference-Abstract-Book.pdf> (last accessed 18 April 2016).
- 34 Bradburn MJ, Deeks JJ, Berlin JA, Localio AR. Much ado about nothing: a comparison of the performance of meta-analytical methods with rare events. *Stat Med* 2007; 26: 53–77.
- 35 Borenstein M, Hedges LV, Higgins JPT, Rothstein HR. A basic introduction to fixed-effect and random-effects models for meta-analysis. *Res Synth Methods* 2010; 1: 97–111.
- 36 Sweeting MJ, Sutton AJ, Lambert PC. What to add to nothing? Use and avoidance of continuity corrections in meta-analysis of sparse data. *Stat Med* 2004; 23: 1351–75.
- 37 Loane M, Dolk H, Morris JK. Maternal age-specific risk of non-chromosomal anomalies. *BJOG* 2009; 116: 1111–9.
- 38 Loane M, Dolk H, Bradbury I. Increasing prevalence of gastroschisis in Europe 1980–2002: a phenomenon restricted to younger mothers? *Paediatr Perinat Epidemiol* 2007; 21: 363–9.
- 39 Harris RJ, Bradburn MJ, Deeks JJ, Altman DG, Harbord RM, Sterne JAC. Metan: fixed- and random-effects meta-analysis. *Stata J* 2008; 8: 3–28.

- 40 Drongowski RA, Smith RK, Coran AG, Klein MD. Contribution of demographic and environmental factors to the etiology of gastroschisis: a hypothesis. *Fetal Diagn Ther* 1991; 6: 14–27.
- 41 Waller DK, Gallaway MS, Taylor LG, Ramadhani TA, Canfield MA, Scheuerle A, *et al.* Use of oral contraceptives in pregnancy and major structural birth defects in offspring. *Epidemiology* 2010; 21: 232–9.
- 42 Torfs CP, Katz EA, Bateson TF, Lam PK, Curry CJ. Maternal medications and environmental exposures as risk factors for gastroschisis. *Teratology* 1996; 54: 84–92.
- 43 Werler MM, Mitchell AA, Shapiro S. First trimester maternal medication use in relation to gastroschisis. *Teratology* 1992; 45: 361–7.
- 44 Lind JN, Tinker SC, Broussard CS, Reefhuis J, Carmichael SL, Honein MA, *et al.* Maternal medication and herbal use and risk for hypospadias: data from the National Birth Defects Prevention Study, 1997–2007. *Pharmacoepidemiol Drug Saf* 2013; 22: 783–93.
- 45 van Rooij IALM, van der Zanden LFM, Brouwers MM, Knoers NVAM, Feitz WFJ, Roeleveld N. Risk factors for different phenotypes of hypospadias: results from a Dutch case-control study. *BJU Int* 2013; 112: 121–8.
- 46 Carmichael SL, Shaw GM, Laurent G, Croughan M, Olney RS, Lammer EJ. Hypospadias and maternal intake of progestins and oral contraceptives. *Birth Defects Res (Part A) Clin Mol Teratol* 2004; 70: 255.
- 47 Sweet RA, Schrott HG, Culp DS. Study of the incidence of hypospadias in Rochester, Minnesota, 1940–70, and a case-control comparison of possible etiologic factors. *Proceedings, Mayo Clin.* 1974; 1: 52–8.
- 48 Kallen B, Castilla EE, Robert E, Lancaster PAL, Kringelbach M, Mutchinick O, *et al.* An international case-control study on hypospadias the problem with variability and the beauty of diversity. *Eur J Epidemiol* 1992; 8: 256–63.
- 49 Levy EP, Cohen A, Fraser FC. Hormone treatment during pregnancy and congenital heart defects. *Lancet* 1973; 301: –611.
- 50 Nora JJ, Nora AH. Birth defects and oral contraceptives. *Lancet* 1973; 301: 941–2.
- 51 Nora J, Nora A, Perinchief A, Ingram J, Fountain A, Peterson M. Congenital abnormalities and first-trimester exposure to progestagen/oestrogen. *Lancet* 1976; 307: 313–4.
- 52 Heinonen OP, Slone DS, Monson RR, Hook EB, Shapiro SS. Cardiovascular birth defects and antenatal exposure to female sex hormones. *N Engl J Med* 1977; 296: 67–70.
- 53 Janerich DT, Dugan JM, Standfast SJ, Strite L. Congenital heart disease and prenatal exposure to exogenous sex hormones. *Br Med J* 1977; 1: 1058–60.
- 54 Nora AH, Nora JJ. A syndrome of multiple congenital anomalies associated with teratogenic exposure. *Arch Environ Heal Int J* 1975; 30: 17–21.
- 55 Jaffe P, Liberman MM, McFadyen I, Valman HB. Incidence of congenital limb-reduction deformities. *Lancet* 1975; 305: 526–7.
- 56 Brent RL. Cardiovascular birth defects and prenatal exposure to female sex hormones: importance of utilizing proper epidemiological methods and teratologic principles. *Teratology* 1994; 49: 159–61.
- 57 Brent RL. Nongenital malformations following exposure to progestational drugs: the last chapter of an erroneous allegation. *Birth Defects Res A Clin Mol Teratol* 2005; 73: 906–18.
- 58 Källén BAJ, Martínez-Frías ML, Castilla EE, Robert E, Lancaster PAL, Kringelbach M, *et al.* Hormone therapy during pregnancy and isolated hypospadias: an international case-control study. *Int J Risk Saf Med* 1992; 3: 183–98.
- 59 Carmichael SL, Shaw GM, Laurent C, Croughan MS, Olney RS, Lammer EJ. Maternal progestin intake and risk of hypospadias. *Arch Pediatr Adolesc Med* 2005; 159: 957–62.
- 60 Meijer WM, de Jong-van den Berg LT, van den Berg MD, Verheij JB, de Walle HE. clomiphene and hypospadias: the necessity to investigate on a detailed level. *Reprod Toxicol* 2005; 3: 472–3.
- 61 Meijer WM, de Jong-Van den Berg LTW, van den Berg MD, Verheij JBG, de Walle HEK. Clomiphene and hypospadias on a detailed level: signal or chance? *Birth Defects Res A Clin Mol Teratol* 2006; 76: 249–52.
- 62 Meijer W, de Walle HE, Bakker MK, van den Berg MD, Verheij JB, de Jong-vanden Berg LT. Association between clomiphene treatment and congenital anomalies. *Pharmacoepidemiol Drug Saf* 2005; 14 (Supplement 2): S74.
- 63 Sørensen HT, Pedersen L, Skriver MV, Nørgaard M, Nørgård B, Hatch EE. Use of clomifene during early pregnancy and risk of hypospadias: population based case-control study. *BMJ* 2005; 330: 126–7.
- 64 Ghassan A-Q, Bassam A-N, Ghazi A-S, Eqab A-M, Elena A-Q. Hypospadias: does the usage of Clomiphene citrate influence the incidence? *Middle East Journal of Family Medicine* 2006. Available at <http://www.mejfm.com/Newarchives2013/Hypospadias.htm> (last accessed 18 April 2016).
- 65 UK Teratology Information Service. Exposure to oral contraceptives in pregnancy [online]. TOXBASE, 2014. Available at http://www.toxbase.org/upload/Pregnancy_pdfs/Oral_Contraceptives_2014.pdf (last accessed 22 August 2014)
- 66 Reefhuis J, Honein MA, Schieve LA, Rasmussen SA. Use of clomiphene citrate and birth defects, National Birth Defects Prevention Study, 1997–2005. *Hum Reprod* 2011; 26: 451–7.
- 67 Pinborg A, Henningsen AK, Malchau SS, Loft A. Congenital anomalies after assisted reproductive technology. *Fertil Steril* 2013; 99: 327–32.
- 68 Davies MJ, Moore VM, Willson KJ, Van Essen P, Priest K, Scott H, *et al.* Reproductive technologies and the risk of birth defects. *N Engl J Med* 2012; 366: 1803–13.
- 69 Elizur SE, Tulandi T. Drugs in infertility and fetal safety. *Fertil Steril* 2008; 89: 1595–602.
- 70 Kumar RM, Hughes PF, Khurranna A. Zidovudine use in pregnancy: a report on 104 cases and the occurrence of birth defects. *J Acquir Immune Defic Syndr* 1994; 7: 1034–9.
- 71 Källén B, Nilsson E, Otterblad Olausson P. Maternal use of loperamide in early pregnancy and delivery outcome. *Acta Paediatr* 2008; 97: 541–5.
- 72 Wilton LV, Pearce GL, Martin RM, Mackay FJ, Mann RD. The outcomes of pregnancy in women exposed to newly marketed drugs in general practice in England. *Br J Obstet Gynaecol* 1998; 105: 882–9.
- 73 Shuhaiber S, Pastuszak A, Schick B, Matsui D, Spivey G, Brochu J, *et al.* Pregnancy outcome following first trimester exposure to sumatriptan. *Neurology* 1998; 51: 581–3.

- 74** Olesen C, Steffensen FH, Sørensen HT. Pregnancy outcome following prescription for sumatriptan. *Headache* 2000; 40: 20–4.
- 75** Nezvalová-Henriksen K, Spigset O, Nordeng H. Triptan safety during pregnancy: a Norwegian population registry study. *Eur J Epidemiol* 2013; 28: 759–69.
- 76** Källén B, Lygner PE. Delivery outcome in women who used drugs for migraine during pregnancy with special reference to sumatriptan. *Headache* 2001; 41: 351–6.
- 77** Ephross SA, Sinclair SM. Final results from the 16-year sumatriptan, naratriptan, and treximet pregnancy registry. *Headache* 2014; 54: 1158–72.
- 78** Källén B, Nilsson E, Otterblad Olausson P. Delivery outcome after maternal use of drugs for migraine: a register study in Sweden. *Drug Saf* 2011; 34: 691–703.
- 79** Fiore M, Shields KE, Santanello N, Goldberg MR. Exposure to rizatriptan during pregnancy: post-marketing experience up to 30 June 2004. *Cephalalgia* 2005; 25: 685–8.
- 80** Nezvalová-Henriksen K, Spigset O, Nordeng H. Triptan exposure during pregnancy and the risk of major congenital malformations and adverse pregnancy outcomes: results from the Norwegian Mother and Child Cohort Study. *Headache* 2010; 50: 563–75.
- 81** Nezvalová-Henriksen K, Spigset O, Nordeng H. Errata in ‘Triptan exposure during pregnancy and the risk of major congenital malformations and adverse pregnancy outcomes: results from the Norwegian Mother and Child Cohort Study’. *Headache* 2012; 52: 1319–20.
- 82** Bánhidly F, Acs N, Puhó EH, Czeizel AE. Chronic hypertension with related drug treatment of pregnant women and congenital abnormalities in their offspring: a population-based study. *Hypertens Res* 2011; 34: 257–63.
- 83** Cooper WO, Hernandez-Diaz S, Arbogast PG, Dudley JA, Dyer S, Gideon PS, *et al.* Major congenital malformations after first-trimester exposure to ACE inhibitors. *N Engl J Med* 2006; 354: 2443–51.
- 84** Li D-K, Yang C, Andrade S, Tavares V, Ferber JR. Maternal exposure to angiotensin converting enzyme inhibitors in the first trimester and risk of malformations in offspring: a retrospective cohort study. *Br Med J (Clin Res Ed)* 2011; 343: d5931.
- 85** Hansen M, Kurinczuk JJ, Milne E, de Klerk N, Bower C. Assisted reproductive technology and birth defects: a systematic review and meta-analysis. *Hum Reprod Update* 2013; 19: 330–53.
- 86** Mayer A, Lunenfeld E, Wiznitzer A, Har-Vardi I, Bentov Y, Levitas E. Increased prevalence of gestational diabetes mellitus in *in vitro* fertilization pregnancies inadvertently conceived during treatment with long-acting triptorelin acetate. *Fertil Steril* 2005; 84: 789–92.
- 87** Abu-Heija AT, Fleming R, Yates RWS, Coutts JRT. Pregnancy outcome following exposure to gonadotrophin-releasing hormone analogue during early pregnancy: comparisons in patients with normal or elevated luteinizing hormone. *Hum Reprod* 1995; 10: 3317–9.
- 88** Platteau P, Gabbe M, Famelos M, Kovacs G, Healy D. Should we still advise infertile couples to use (barrier) contraception before IVF down-regulation? *Fertil Steril* 2000; 74: 655–9.
- 89** Elefant E, Biour B, Blumberg-Tick J, Roux C, Thomas F. Administration of a gonadotropin-releasing hormone agonist during pregnancy: follow-up of 28 pregnancies exposed to triptoreline. *Fertil Steril* 1995; 63: 1111–3.
- 90** Sørensen HT, Nielsen GL, Christensen K, Tage-Jensen U, Ekbohm A, Baron J. Birth outcome following maternal use of metoclopramide. *Br J Clin Pharmacol* 2000; 49: 264–8.
- 91** Berkovitch M, Mazzota P, Greenberg R, Elbirt D, Addis A, Schuler-Faccini L, *et al.* Metoclopramide for nausea and vomiting of pregnancy: a prospective multicenter international study. *Am J Perinatol* 2002; 19: 311–6.
- 92** Choi J-S, Han J-Y, Ahn H-K, Ryu H-M, Kim M-Y, Yang J-H, *et al.* Fetal and neonatal outcomes in women taking domperidone during pregnancy. *J Obstet Gynaecol* 2013; 33: 160–2.
- 93** Addis A, Bailey B, Lee A, Lau M, Koren G. Safety of cisapride use during pregnancy: a prospective controlled cohort study. *Teratology* 1997; 55: 100.
- 94** Bailey B, Addis A, Lee A, Sanghvi K, Mastroiacovo P, Mazzone T, *et al.* Cisapride use during human pregnancy: a prospective, controlled multicenter study. *Dig Dis Sci* 1997; 42: 1848–52.
- 95** Anderka M, Mitchell AA, Louik C, Werler MM, Hernández-Diaz S, Rasmussen SA. Medications used to treat nausea and vomiting of pregnancy and the risk of selected birth defects. *Birth Defects Res A Clin Mol Teratol* 2012; 94: 22–30.
- 96** Pasternak B, Svanström H, Mølgaard-Nielsen D, Melbye M, Hviid A. Metoclopramide in pregnancy and risk of major congenital malformations and fetal death. *J Am Med Assoc* 2013; 310: 1601–11.
- 97** Matok I, Gorodischer R, Koren G, Sheiner E, Wiznitzer A, Levy A. The safety of metoclopramide use in the first trimester of pregnancy. *N Engl J Med* 2009; 360: 2528–35.
- 98** Garne E, Dolk H, Loane M, Boyd PA, on behalf of EUROCAT. EUROCAT website data on prenatal detection rates of congenital anomalies. *J Med Screen* 2010; 17: 97–8.
- 99** de Jonge L, Garne E, Gini R, Jordan SE, Klungsoyr K, Loane M, *et al.* Improving information on maternal medication use by linking prescription data to congenital anomaly registers: a EUROmediCAT study. *Drug Saf* 2015; 38: 1083–93.
- 100** Xu R, Wang Q. Large-scale combining signals from both biomedical literature and the FDA Adverse Event Reporting System (FAERS) to improve post-marketing drug safety signal detection. *BMC Bioinformatics* 2014; 15: 17.
- 101** Brent RL. The cause and prevention of human birth defects: what have we learned in the past 50 years? *Congenit Anom (Kyoto)* 2001; 41: 3–21.
- 102** Garlapati S, Priyanka S. Cradles of signals for pharmacovigilance process. *J Pharmacovigil* 2014; 3: 1–2.
- 103** Bánhidly F, Dakhlaoui A, Puhó EH, Czeizel AE. Peptic ulcer disease with related drug treatment in pregnant women and congenital abnormalities in their offspring. *Congenit Anom (Kyoto)* 2011; 51: 26–33.
- 104** Jick H, Holmes LB, Hunter JR, Madsen S, Stergachie A. First-trimester drug use and congenital disorders. *J Am Med Assoc* 1981; 246: 343–6.
- 105** Einarson A, Mastroiacovo P, Arnon J, Ornoy A, Addis A. Prospective, controlled, multicentre study of loperamide in pregnancy. *Can J Gastroenterol* 2000; 14: 1999–2001.
- 106** Czeizel AE, Vass J. Teratological surveillance of oral contraceptive use in early pregnancy. *Adv Contracept Deliv Syst* 1996; 12: 51–9.
- 107** World Health Organization. The effect of female sex hormones on fetal development and infant health [online]. World Health

- Organization technical report series, 1981; 1–76. Available at <http://www.ncbi.nlm.nih.gov/pubmed/6785928> (last accessed 18 April 2016).
- 108** Bracken MB. Oral contraception and congenital malformations in offspring: a review and meta-analysis of the prospective studies. *Obstet Gynecol* 1990; 76 (3 Part 2): 552–7.
- 109** Kasan PN, Andrews J. Oral contraception and congenital abnormalities. *Br J Obstet Gynaecol* 1980; 87: 545–51.
- 110** Cuckle HS, Wald NJ. Evidence against oral contraceptives as a cause of neural-tube defects. *Br J Obstet Gynaecol* 1982; 89: 547–9.
- 111** Shaw GM, Todoroff K, Velie EM, Lammer EJ. Maternal illness, including fever, and medication use as risk factors for neural tube defects. *Teratology* 1998; 57: 1–7.
- 112** Hill L, Murphy M. Maternal drug histories and congenital malformations: limb reduction defects and oral clefts. *J Epidemiol Community Health* 1988; 42: 1–7.
- 113** Raman-Wilms L, Tseng AL, Wighardt S, Einarson TR, Koren G. Fetal genital effects of first-trimester sex hormone exposure: a meta-analysis. *Obstet Gynecol* 1995; 85: 141–9.
- 114** Wogelius P, Horváth-Puhó E, Pedersen L, Nørgaard M, Czeizel AE, Sørensen HT. Maternal use of oral contraceptives and risk of hypospadias – a population-based case-control study. *Eur J Epidemiol* 2006; 21: 777–81.
- 115** Nørgaard M, Wogelius P, Pedersen L, Rothman KJ, Sørensen HT. Maternal use of oral contraceptives during early pregnancy and risk of hypospadias in male offspring. *Urology* 2009; 74: 583–7.
- 116** Bjerkedal T, Bakketeig LS. Orientering om en undersøkelse over årsaken till en registrert øking av misdannelser i urin-og kjønnsorganer. *Tidsskr Nor Laegefor* 1975; 95: 1436–7.
- 117** Li DK, Daling JR, Mueller BA, Hickok DE, Fantel AG, Weiss NS. Oral contraceptive use after conception in relation to the risk of congenital urinary tract anomalies. *Teratology* 1995; 51: 30–6.
- 118** Varma TR, Morsman J. Evaluation of the use of prolation-depot (hydroxyprogesterone hexanoate) in early pregnancy. *Int J Gynecol Obstet* 1982; 20: 13–7.
- 119** Michaelis J, Michaelis H, Glück E, Koller S. Prospective study of suspected associations between certain drugs administered during early pregnancy and congenital malformations. *Teratology* 1983; 27: 57–64.
- 120** Resseguie LJ, Hick JF, Bruen JA, Noller KL, O'Fallon WM, Kurland LT. Congenital malformations among offspring exposed *in utero* to progestins, Olmsted county, Minnesota, 1936–1974. *Fertil Steril* 1985; 43: 514–9.
- 121** Katz Z, Lancet M, Skornik J, Chemke J, Mogilner BM, Klinberg M. Teratogenicity of progestogens given during the first trimester of pregnancy. *Obstet Gynecol* 1985; 65: 775–80.
- 122** Lammer EJ, Cordero JF. Exogenous sex hormone exposure and the risk for major malformations. *JAMA* 1986; 255: 3128–32.
- 123** Heinonen OP, Slone D, Shapiro S. *Birth Defects and Drugs in Pregnancy*. Littleton, MA: Publishing Sciences Group, 1977.
- 124** Yovich JL, Turner SR, Draper R. Medroxyprogesterone acetate therapy in early pregnancy has no apparent fetal effects. *Teratology* 1988; 38: 135–44.
- 125** Colvin L, Slack-Smith L, Stanley FJ, Bower C. Linking a pharmaceutical claims database with a birth defects registry to investigate birth defect rates of suspected teratogens. *Pharmacoepidemiol Drug Saf* 2010; 19: 1137–50.
- 126** Dudás I, Gidai J, Czeizel AE. Population-based case-control teratogenic study of hydroxyprogesterone treatment during pregnancy. *Congenit Anom (Kyoto)* 2006; 46: 194–8.
- 127** Carmichael SL, Shaw GM, Laurent C, Croughan MS, Olney RS, Lammer EJ. Maternal progestin intake and risk of hypospadias. *Arch Pediatr Adolesc Med* 2005; 159: 957–62.
- 128** Baeka K, Rosenwaks Z, Poppasa DP, Palermoa GD. Does progesterone administration increase the incidence of neonatal hypospadias? *Fertil Steril* 2006; 86 (Supplement 2): S337.
- 129** Chez RA. Proceedings of the symposium 'progesterone, progestins, and fetal development'. *Fertil Steril* 1978; 30: 16–26.
- 130** Rothman KJ, Fyler DC, Goldblatt A, Kreidberg MB. Exogenous hormones and other drug exposures of children with congenital heart disease. *Am J Epidemiol* 1979; 109: 433–9.
- 131** Queisser-Luft A. Dydrogesterone use during pregnancy: overview of birth defects reported since 1977. *Early Hum Dev* 2009; 85: 375–7.
- 132** El-Zibdeh MY. Dydrogesterone in the reduction of recurrent spontaneous abortion. *J Steroid Biochem Mol Biol* 2005; 97: 431–4.
- 133** El-Zibdeh MY, Yousef LT. Dydrogesterone support in threatened miscarriage. *Maturitas* 2009; 65 (Supplement 1): S43–6.
- 134** Pandian RU. Dydrogesterone in threatened miscarriage: a Malaysian experience. *Maturitas* 2009; 65 (Suppl 1): S47–50.
- 135** Greenland S, Ackerman DL. Clomiphene citrate and neural tube defects: a pooled analysis of controlled epidemiologic studies and recommendations for future studies. *Fertil Steril* 1995; 64: 936–41.
- 136** Medveczky E, Puhó E, Czeizel EA. The use of drugs in mothers of offspring with neural-tube defects. *Pharmacoepidemiol Drug Saf* 2004; 13: 443–55.
- 137** Wu YW, Croen LA, Henning L, Najjar DV, Schembri M, Croughan MS. A potential association between infertility and spinal neural tube defects in offspring. *Birth Defects Res A Clin Mol Teratol* 2006; 76: 718–22.
- 138** Loffredo CA, Ferencz C, Rubin JD, Correa-Villaseñor A, Wilson PD. A comparative epidemiologic evaluation of risk factors for hypoplastic left heart syndrome, aortic stenosis, and coarctation of the aorta. *Teratology* 1996; 53: 115.
- 139** Joao EC, Calvet GA, Krauss MR, Hance F, Ortiz J, Ivalo SA, et al. Maternal antiretroviral use during pregnancy and infant congenital anomalies: the NISDI Perinatal Study. *J Acquir Immune Defic Syndr* 2010; 53: 176–85.
- 140** Patel D, Thorne C, Fiore S, Newell M-L. Does highly active antiretroviral therapy increase the risk of congenital abnormalities in HIV-infected women? *J Acquir Immune Defic Syndr* 2005; 40: 116–8.
- 141** Knapp KM, Brogly SB, Muenz DG, Spiegel HML, Conway DH, Scott GB, et al. Prevalence of congenital anomalies in infants with *in utero* exposure to antiretrovirals. *Pediatr Infect Dis J* 2012; 31: 164–70.
- 142** Floridia M, Mastroiacovo P, Tamburrini E, Tibaldi C, Todros T, Crepaldi A, et al. Birth defects in a national cohort of pregnant women with HIV infection in Italy, 2001–2011. *BJOG* 2013; 120: 1466–75.

- 143** Sibiude J, Mandelbrot L, Blanche S, Le Chenadec J, Boullag-Bonnet N, Faye A, *et al.* Association between prenatal exposure to antiretroviral therapy and birth defects: an analysis of the French perinatal cohort study (ANRS CO1/CO11). *PLoS Med* 2014; 11: e1001635.
- 144** Brogly SB, Abzug MJ, Watts DH, Cunningham CK, Williams PL, Oleske J, *et al.* Birth defects among children born to human immunodeficiency virus-infected women: pediatric AIDS clinical trials protocols 219 and 219C. *Pediatr Infect Dis J* 2011; 29: 721–7.
- 145** Antiretroviral Pregnancy Registry Steering Committee. Antiretroviral Pregnancy Registry International Interim Report for 1 January 1989 through 31 July 2011, 2014.
- 146** Newschaffer CJ, Cocroft J, Anderson CE, Hauck WW, Turner BJ. Prenatal zidovudine use and congenital anomalies in a medicaid population. *J Acquir Immune Defic Syndr* 2000; 24: 249–56.
- 147** Watts DH, Huang S, Culnane M, Kaiser KA, Mofenson L, Stanley K, *et al.* Birth defects among a cohort of infants born to HIV-infected women on antiretroviral medication. *J Perinat Med*. 2011; 39: 163–70.
- 148** Watts DH, Li D, Handelsman E, Tilson H, Paul M, Foca M, *et al.* Assessment of birth defects according to maternal therapy among infants in the Women and Infants Transmission Study. *J Acquir Immune Defic Syndr* 2007; 44: 299–305.

Supporting Information

Additional Supporting Information may be found in the online version of this article at the publisher's web-site:

<http://onlinelibrary.wiley.com/doi/10.1111/bcp.12947/supinfo>.

Table S1 EUROmediCAT signal detection dataset
Document S1 Literature review methodology